| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
| 5 | 11 | 14 | 20 | 29 | |
Growth YoY Revenue Growth YoY% | 173.0 | 80.1 | 109.4 | ||
| 4 | 8 | 11 | 16 | 23 | |
| 1 | 3 | 3 | 4 | 6 | |
OPM OPM% | 22.3 | 23.8 | 23.5 | 18.3 | 20.7 |
| 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 |
PBT PBTCr | 1 | 2 | 3 | 3 | 6 |
| 0 | 0 | 1 | 1 | 1 | |
| 1 | 2 | 2 | 3 | 5 | |
Growth YoY PAT Growth YoY% | 198.7 | 56.4 | 103.0 | ||
NPM NPM% | 15.2 | 15.8 | 16.6 | 13.8 | 16.1 |
| 16.0 | 4.7 | 4.7 | 4.5 | 6.5 |
| Quarter | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
| 5 | 11 | 14 | 20 | 29 | |
Growth YoY Revenue Growth YoY% | 173.0 | 80.1 | 109.4 | ||
| 4 | 8 | 11 | 16 | 23 | |
| 1 | 3 | 3 | 4 | 6 | |
OPM OPM% | 22.3 | 23.8 | 23.5 | 18.3 | 20.7 |
| 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 |
PBT PBTCr | 1 | 2 | 3 | 3 | 6 |
| 0 | 0 | 1 | 1 | 1 | |
| 1 | 2 | 2 | 3 | 5 | |
Growth YoY PAT Growth YoY% | 198.7 | 56.4 | 103.0 | ||
NPM NPM% | 15.2 | 15.8 | 16.6 | 13.8 | 16.1 |
| 16.0 | 4.7 | 4.7 | 4.5 | 6.5 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
Revenue RevenueCr | 3 | 5 | 16 | 34 | 49 |
Growth Revenue Growth% | 72.4 | 219.7 | 110.0 | 96.6 | |
| 2 | 4 | 12 | 27 | 39 | |
| 1 | 1 | 4 | 7 | 10 | |
OPM OPM% | 21.4 | 24.4 | 23.3 | 20.5 | 19.7 |
| 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 |
PBT PBTCr | 0 | 1 | 3 | 6 | 9 |
| 0 | 0 | 1 | 1 | 1 | |
PAT PATCr | 0 | 1 | 3 | 5 | 7 |
Growth PAT Growth% | 192.9 | 204.3 | 102.7 | 83.2 | |
NPM NPM% | 9.7 | 16.4 | 15.6 | 15.1 | 15.2 |
| 7.8 | 22.8 | 6.9 | 9.3 | 11.1 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
Revenue RevenueCr | 3 | 5 | 16 | 34 | 49 |
Growth Revenue Growth% | 72.4 | 219.7 | 110.0 | 96.6 | |
| 2 | 4 | 12 | 27 | 39 | |
| 1 | 1 | 4 | 7 | 10 | |
OPM OPM% | 21.4 | 24.4 | 23.3 | 20.5 | 19.7 |
| 0 | 0 | 0 | 0 | 0 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 |
PBT PBTCr | 0 | 1 | 3 | 6 | 9 |
| 0 | 0 | 1 | 1 | 1 | |
PAT PATCr | 0 | 1 | 3 | 5 | 7 |
Growth PAT Growth% | 192.9 | 204.3 | 102.7 | 83.2 | |
NPM NPM% | 9.7 | 16.4 | 15.6 | 15.1 | 15.2 |
| 7.8 | 22.8 | 6.9 | 9.3 | 11.1 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 0 | 0 | 0 | 7 | 7 |
Reserves ReservesCr | 0 | 1 | 5 | 28 | 33 |
| 2 | 3 | 3 | 3 | ||
| 1 | 1 | 2 | 4 | ||
| 4 | 5 | 11 | 42 | 50 | |
| 3 | 3 | 9 | 30 | ||
| 1 | 1 | 2 | 12 | ||
| 4 | 5 | 11 | 42 | 50 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 0 | 0 | 0 | 7 | 7 |
Reserves ReservesCr | 0 | 1 | 5 | 28 | 33 |
| 2 | 3 | 3 | 3 | ||
| 1 | 1 | 2 | 4 | ||
| 4 | 5 | 11 | 42 | 50 | |
| 3 | 3 | 9 | 30 | ||
| 1 | 1 | 2 | 12 | ||
| 4 | 5 | 11 | 42 | 50 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1 | 0 | -2 | -9 | |
| 0 | 0 | -1 | -15 | |
| -1 | 0 | 3 | 25 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 0 | 1 |
Free Cash Flow Free Cash FlowCr | 1 | 0 | -3 | -15 |
CFO To PAT CFO To PAT% | 242.8 | 28.0 | -88.6 | -185.9 |
CFO To EBITDA CFO To EBITDA% | 109.6 | 18.8 | -59.5 | -136.7 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1 | 0 | -2 | -9 | |
| 0 | 0 | -1 | -15 | |
| -1 | 0 | 3 | 25 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 | 0 | 1 |
Free Cash Flow Free Cash FlowCr | 1 | 0 | -3 | -15 |
CFO To PAT CFO To PAT% | 242.8 | 28.0 | -88.6 | -185.9 |
CFO To EBITDA CFO To EBITDA% | 109.6 | 18.8 | -59.5 | -136.7 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 151 | 232 | |||
Price To Earnings Price To Earnings | 29.7 | 28.9 | |||
Price To Sales Price To Sales | 4.5 | 4.7 | |||
Price To Book Price To Book | 4.2 | 6.5 | |||
EV To EBITDA EV To EBITDA | 21.0 | ||||
GPM GPM% | 35.3 | 36.1 | 29.8 | 25.7 | 25.7 |
OPM OPM% | 21.4 | 24.4 | 23.3 | 20.5 | 19.7 |
NPM NPM% | 9.7 | 16.4 | 15.6 | 15.1 | 15.2 |
ROCE ROCE% | 21.4 | 35.4 | 39.4 | 17.0 | 20.6 |
ROE ROE% | 106.7 | 75.8 | 49.5 | 14.3 | 18.5 |
ROA ROA% | 6.9 | 17.7 | 23.7 | 12.1 | 14.8 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 151 | 232 | |||
Price To Earnings Price To Earnings | 29.7 | 28.9 | |||
Price To Sales Price To Sales | 4.5 | 4.7 | |||
Price To Book Price To Book | 4.2 | 6.5 | |||
EV To EBITDA EV To EBITDA | 21.0 | ||||
GPM GPM% | 35.3 | 36.1 | 29.8 | 25.7 | 25.7 |
OPM OPM% | 21.4 | 24.4 | 23.3 | 20.5 | 19.7 |
NPM NPM% | 9.7 | 16.4 | 15.6 | 15.1 | 15.2 |
ROCE ROCE% | 21.4 | 35.4 | 39.4 | 17.0 | 20.6 |
ROE ROE% | 106.7 | 75.8 | 49.5 | 14.3 | 18.5 |
ROA ROA% | 6.9 | 17.7 | 23.7 | 12.1 | 14.8 |
| Market CapitalizationMkt CapCr | 237 | 233 | 233 | 232 | 205 | 202 | 198 |
| Close PriceClose₹ | 150.00 | 38.16 | 404.00 | 320.00 | 167.10 | 160.70 | 67.20 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 12.40 | 20.45 | 28.93 | 20.60 | 0.28 | 2.72 | |
| Price To SalesPS | 1.06 | 5.75 | 2.29 | 4.73 | 2.43 | 3.12 | 2.51 |
| RevenueRevenueCr | 224 | 41 | 101 | 49 | 84 | 65 | 79 |
| Revenue Growth TTMRev Gr TTM% | 26.7% | -8.4% | 41.8% | 96.6% | 22.5% | -14.9% | |
| PAT Growth TTMPAT Gr TTM% | 43.3% | -238.4% | 16.6% | 83.2% | 33.6% | 421.4% |
| Market CapitalizationMkt CapCr | 237 | 233 | 233 | 232 | 205 | 202 | 198 |
| Close PriceClose₹ | 150.00 | 38.16 | 404.00 | 320.00 | 167.10 | 160.70 | 67.20 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 12.40 | 20.45 | 28.93 | 20.60 | 0.28 | 2.72 | |
| Price To SalesPS | 1.06 | 5.75 | 2.29 | 4.73 | 2.43 | 3.12 | 2.51 |
| RevenueRevenueCr | 224 | 41 | 101 | 49 | 84 | 65 | 79 |
| Revenue Growth TTMRev Gr TTM% | 26.7% | -8.4% | 41.8% | 96.6% | 22.5% | -14.9% | |
| PAT Growth TTMPAT Gr TTM% | 43.3% | -238.4% | 16.6% | 83.2% | 33.6% | 421.4% |